Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice.
|
| Abstract |
Pretomanid (PA-824), a novel anti-tuberculosis (TB) nitroimidazoxazine, has been approved for multi-drug-resistant TB treatment for a few years. Pretomanid has been demonstrated to be highly active against Mycobacterium tuberculosis when combined with other anti-TB drugs. This review provides an update of the current knowledge on the modes of action, resistance mechanisms, emergence of drug resistance, and status of antimicrobial susceptibility testing for pretomanid and its relevance for clinical practice. Pretomanid resistance has been reported in in-vitro and animal models but not yet in clinical trials. Pretomanid-resistance-associated mutations have been reported in the fbiA, fbiB, fbiC, fbiD, ddn and fgd1 genes. However, understanding of in-vivo molecular resistance mechanisms remains limited, and complicates the development of accurate antimicrobial susceptibility testing methods for pretomanid. As such, no reference method for antimicrobial susceptibility testing of pretomanid has been established to guide clinical use. Further studies linking specific mutations, in-vitro susceptibility, drug exposure and resistance mechanisms to treatment failure with pretomanid should be prioritized.
|
|---|---|
| Authors | Thi Van Anh Nguyen, Quang Huy Nguyen, Tran Nam Tien Nguyen, Richard M Anthony, Dinh Hoa Vu, Jan-Willem C Alffenaar |
| Journal | International journal of antimicrobial agents (Int J Antimicrob Agents) Vol. 62 Issue 4 Pg. 106953 (Oct 2023) ISSN: 1872-7913 [Electronic] Netherlands |
| PMID | 37595848 (Publication Type: Journal Article, Review) |
| Copyright | Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!